XERIS BIOPHARMA HOLDINGS, INC. Cost of Revenue
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Cost of Revenue of $3.22 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2021-11-10
- XERIS BIOPHARMA HOLDINGS, INC. cost of goods and services sold for the quarter ending 2021-09-30 was $3.22M, a 13.70% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. cost of goods and services sold for the quarter ending 2020-09-30 was $2.83M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 9 month |
|---|---|---|
| 2021-09-30 | $3.22M 10-Q · filed 2021-11-10 | $8.43M 10-Q · filed 2021-11-10 |
| 2020-09-30 | $2.83M 10-Q · filed 2021-11-10 | $5.92M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |